Omeros Corporation (OMER) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Omeros (OMER) Q1 2026: Yartemlia Launch Reaches 30 Sites, Accelerating Standard of Care Ambitions
May 14, 2026
-
Omeros (OMER) Q4 2025: $240M Novo Nordisk Deal and Yartemlia Launch Reset Growth Trajectory
April 01, 2026
-
Omeros (OMER) Q3 2025: $2.1B Novo Nordisk Deal Reshapes Capital and Pipeline Trajectory
November 14, 2025
-
Omeros (OMER) Q2 2025: Debt Reduced by $100M as Narsoplimab Approval Nears
August 15, 2025
-
Omeros (OMER) Q1 2025: $100M Debt Extension Unlocks Launch Path for Narsoplimab
July 03, 2025